[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Chao Yang Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":577},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,44,68,88,112,136,157,177,202,221,251,278,298,325,347,367,386,408,435,456,476,495,516,532,553],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100641302","fapl-imaging-assessment-of-revascularization-outcome-in-ischemic-heart-failure-100641302",false,"NCT07657650","FAPl Imaging Assessment of Revascularization Outcome in Ischemic Heart Failure","FARO","Inclusion Criteria:\n\n① Age ≥ 18 years; ② Meet the above-mentioned IHF diagnostic criteria; ③ Coronary angiography shows suitability for revascularization (PCI or CABG); ④ NYHA cardiac function classification is II-IV; ⑤ Sign the informed consent form.\n\nExclusion Criteria:\n\n① Heart failure caused by non-ischemic etiologies (such as dilated cardiomyopathy, valvular heart disease, myocarditis, etc.); ② Acute myocardial infarction occurred within the last 3 months; ③ Expected lifespan \\\u003C 1 year; ④ Complicated with other severe systemic diseases; ⑤ Has a history of tumors; ⑥ Has any conditions that are unsuitable for revascularization (such as uncorrectable coagulation dysfunction, active bleeding, etc.)","ALL","18 Years",{"count":20,"type":21},122,"ESTIMATED","OBSERVATIONAL","Ischemic heart failure (IHF) is the final stage of coronary heart disease. Coronary revascularization is an important treatment method for IHF, but it has high perioperative risks and not all patients can benefit from it. Evaluation of viable myocardium is one of the important decision-making methods for IHF, but recent research results have raised doubts about its value. The clinical community urgently needs more precise and comprehensive non-invasive decision-making methods. Fibroblast activation protein inhibitor (FAPI) imaging can specifically identify activated fibroblasts and achieve non-invasive diagnosis of the early and reversible stage of myocardial injury. Previous studies have shown that FAPI imaging can identify more damaged myocardium in various heart diseases compared to existing imaging techniques, demonstrating good clinical application potential. This study aims to conduct a prospective cohort trial for IHF patients who have undergone revascularization, using 18F-FAPI and viable myocardium (18F-FDG) imaging to analyze the degree of improvement in left ventricular ejection fraction after revascularization and major adverse cardiovascular events, and to explore the independent or additive predictive value of 18F-FAPI imaging, in order to provide a more reliable non-invasive imaging decision-making method for the revascularization strategy of IHF patients.",[25],"Ischemic Heart Failure",[27,28,29,30],"Ischemic heart failure","Revascularization","Fibroblast activation","Molecular imaging","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2026-04-10",{"date":39,"type":21},"2028-12-31",{"name":41,"class":42},"Beijing Chao Yang Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":43},"100609071","phase-4-sis-reinforced-vs-conventional-anastomosis-for-mid-to-low-rectal-cancer-a-multicenter-rct-on-anastomotic-leak-100609071","NCT07209787","SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak","A Prospective, Multicenter, Randomized Controlled Study Comparing Effect of Conventional Versus SIS-Reinforced Rectum Anastomosis On Anastomotic Leak Following Radical Resection of Mid-to-Low Rectal Cancer（SISReal）","Inclusion Criteria--\n\n1. Age ≤ 85 years old, regardless of gender.\n2. Patients with mid - low rectal cancer, where the lower edge of the cancer focus is ≤ 10 cm from the anus and who can undergo rectal anastomosis with a circular stapler (including mid - low and some ultra - low rectal anastomoses). This includes patients after neoadjuvant therapy, patients with insufficient function of important organs such as the heart, liver, and kidneys who can tolerate surgery, and patients after intestinal obstruction stent placement or chemotherapy after intestinal obstruction stent placement.\n3. For patients who, after being fully informed by doctors, still clearly refuse neoadjuvant therapy (for advanced rectal cancer) and\u002For immunotherapy (for MSI - H\u002FdMMR rectal cancer) and request direct surgery, they are generally not included in this study. If a patient insists on enrolling, the operating surgeon must have a second conversation with the patient and\u002For their family members, and sign in the medical record to confirm the following: The patient is aware of the existence of the neoadjuvant therapy\u002Fimmunotherapy pathway but refuses the relevant treatment and insists on direct surgery. Only in this case can the patient be allowed to enroll.\n4. Patients who received conversion therapy due to distant organ (such as liver, lung) metastasis before surgery and then underwent surgery with primary anastomosis can be included in this study. If organ metastasis is accidentally found during surgery, or if the small intestine or bladder in the pelvic floor is invaded, but the surgeon believes it does not affect rectal anastomosis, the patient does not need to withdraw from the study.\n5. The patient or their authorized representative voluntarily signs the informed consent form and can cooperate to complete the follow - up during the trial.\n\nExclusion Criteria--\n\n1. Patients who, through examination and pre - operative consultation, cannot tolerate routine surgery.\n2. Patients who are currently participating in other clinical studies.\n3. Since the test device (SIS reinforcement patch) is derived from porcine - sourced materials, out of respect for specific religious beliefs (such as Islam), we do not recommend that subjects whose beliefs prohibit contact with porcine - sourced products participate in this study. We will fully communicate this situation with all potential subjects, and the subjects will make their own decisions based on their personal beliefs and cultural backgrounds.\n4. Patients who do not meet the NCCN and the National Health Commission of China's treatment standards for rectal cancer will not be included in this study. For example, patients who should receive neoadjuvant therapy before surgery should preferentially choose neoadjuvant therapy, and MSI - H\u002FdMMR patients are required to undergo immunotherapy first.\n5. Due to the possible difficulty in matching the number of patients\u002Fomissions with regular patients, patients who require lateral lymph node dissection and those who receive Ta - TME will not be included in this study.\n6. Patients who, due to language or intellectual disabilities, cannot understand the content of the trial protocol, cannot complete the follow - up, or for whom the researcher deems there are other situations that are not suitable for enrollment (such as uncontrolled severe underlying diseases, mental illness, etc.).","85 Years",{"count":53,"type":21},966,"INTERVENTIONAL",[56],"PHASE4","The goal of this clinical trial is to learn whether using a reinforcing material called SIS (small intestinal submucosa) during bowel connection after rectal cancer surgery can help prevent anastomotic leakage-a serious complication where the connection between two parts of the intestine fails to heal properly. This study will focus on patients with mid-to-low rectal cancer who are scheduled for surgery.\n\nThe main questions the study aims to answer are:\n\nDoes using an SIS-reinforced connection reduce the rate of anastomotic leakage within 30 days after surgery compared to standard connection methods?\n\nDoes it also reduce the need for a temporary stoma (an opening in the abdomen for waste removal)?\n\nResearchers will compare two groups:\n\nIntervention group: Patients who receive the SIS-reinforced connection during surgery.\n\nControl group: Patients who receive the standard connection without reinforcement.\n\nParticipants in this study will:\n\nBe randomly assigned to either the intervention or control group.\n\nUndergo standard laparoscopic or robot-assisted rectal cancer surgery.\n\nBe followed up at 30 days, 90 days, and 12 months after surgery to check for complications, stoma status, and quality of life.\n\nThis study is being conducted across multiple hospitals in China to ensure the results are reliable and widely applicable.",[59],"Rectal Cancer","2026-06-15",{"date":62,"type":35},"2026-06-17",{"date":64,"type":35},"2025-10-21",{"date":66,"type":21},"2027-08-31",{"name":41,"class":42},{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":54,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":43},"100568044","a-novel-strategy-of-ecmo-management-using-nafamostat-for-regional-combined-with-low-intensity-systematic-anticoagulation-100568044","NCT06676085","A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation","A Novel Strategy Combined Regional Anticoagulation in Membrane Oxygenator and Low-intensity of Systemic Anticoagulation Applied in Management of Extracorporeal Membrane Oxygenation","Inclusion Criteria:\n\n* age older than 18 years old\n* received ECMO because of severe respiratory failure\n\nExclusion Criteria:\n\n* anticoagulant contraindications\n* cerebral infarction or suspected patients\n* severe hypertension\n* women in gestational and lactational period\n* hemophilia\n* allergic to heparin or Nafamostat\n* unwilling or unable to complete the study",{"count":76,"type":21},140,[78],"NA","ECMO is widely used in patients with refractory respiratory and\u002For circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.",[81],"ECMO",{"date":62,"type":35},{"date":84,"type":35},"2024-11-01",{"date":86,"type":21},"2027-12-31",{"name":41,"class":42},{"id":89,"slug":90,"hasResults":12,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":54,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":111,"locationsCount":43},"100636283","phase-4-early-low-dose-aspirin-use-after-intravenous-thrombolysis-for-acute-ischemic-cerebral-infarctionelastic-100636283","NCT07563673","Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction（ELASTIC）","Safety and Efficacy of Treatment With Early Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction (ELASTIC): A Randomized, Open-label, Blinded Endpoint, Clinical Trial","ELASTIC","Inclusion Criteria:\n\n1. Age range: 18-65 years old\n2. Receive rt PA thrombolytic therapy within 3 hours (including 3 hours) of onset\n3. Signs of brain dysfunction lasting for more than 1 hour\n4. CT imaging excludes cerebral hemorrhage, and there are no imaging changes corresponding to the patient's physical signs\n\nExclusion Criteria:\n\n1. Age\\>65 years old\n2. Onset time\\>3 hours\n3. Accompanied by consciousness disorders, or NIHSS ≥ 20 points\n4. CT shows' high-density shadow of middle cerebral artery '\n5. Accompanied by atrial fibrillation or clearly identified as cardioembolic embolism\n6. Severe swallowing difficulties, unable to take medication orally\n7. Oral anticoagulant medication is currently being taken\n8. Accompanied by severe infection or evidence of severe infection\n9. Refusal to sign the informed consent form for this study\n10. Exclusion criteria for other traditional intravenous thrombolysis","65 Years",{"count":98,"type":21},210,[56],"This study evaluates whether early administration of low-dose aspirin (100mg) at 2 hours post-intravenous thrombolysis, compared to the standard timing of 24 hours, improves functional outcomes in patients with acute ischemic stroke. Intravenous thrombolysis is effective for very early treatment of acute ischemic stroke. However, current guidelines recommend starting antiplatelet therapy 24 hours after thrombolysis to avoid symptomatic intracranial hemorrhage (SICH), a recommendation not based on prospective clinical studies. Early re-occlusion of recanalized arteries due to platelet aggregation occurs in 14-34% of cases and is associated with poor prognosis. The average incidence of SICH is 2.4%, with fatal SICH occurring in only 0.28%. Thus, the impact of re-occlusion on poor prognosis may outweigh the risk of SICH. In this prospective, randomized, open-label trial with blinded endpoint evaluation, participants are assigned to receive aspirin 100mg either at 2 hours (early group) or at 24 hours (standard group) after thrombolysis. The primary outcome is the proportion of patients with a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-2 at 3 months. Safety outcomes include the incidence of SICH and all-cause mortality at 3 months. This study will provide clinical evidence regarding the optimal timing for initiating antiplatelet therapy after thrombolysis in acute ischemic stroke.",[102,103],"Cerebral Infarction","Thrombolysis","NOT_YET_RECRUITING","2026-05-05",{"date":107,"type":35},"2026-05-08",{"date":109,"type":21},"2026-05-01",{"date":86,"type":21},{"name":41,"class":42},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":118,"targetDuration":120,"studyType":22,"phases":4,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100589152","development-and-application-of-a-thrombosis-risk-prediction-model-in-lung-cancer-patients-treated-with-immune-checkpoint-inhibitors-100589152","NCT06950697","Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n* Age ≥18 years\n* Histopathologically confirmed lung cancer diagnosis at enrollment\n* Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Presence of two or more primary cancers\n* Missing data for key variables\n* Inability to comply with follow-up requirements\n* Presence of VTE\u002FATE at the time of ICI initiation",{"count":119,"type":21},2400,"30 Months","The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint inhibitors (ICIs) therapy. The primary questions it aims to address are:\n\n1. What is the real-world incidence of VTE\u002FATE in lung cancer patients receiving immune checkpoint inhibitors?\n2. What are the risk factors and biomarkers for VTE\u002FATE in lung cancer patients receiving immune checkpoint inhibitors?\n3. What is the impact of VTE\u002FATE on the prognosis of lung cancer patients receiving immune checkpoint inhibitors?\n\nResearchers will compare the characteristics and biomarkers of patients with and without ICI-associated VTE\u002FATE to identify novel specific biomarkers for thrombotic events. Furthermore, they will construct a risk assessment model for thrombotic events to provide guidance for precision prevention and treatment in clinical practice.",[123,124,125,126],"Lung Cancer","Venous Thromboembolism","Arterial Thromboembolism","Immune Checkpoint Inhibitors (ICIs)","2026-04-26",{"date":129,"type":35},"2026-04-30",{"date":131,"type":35},"2019-01-01",{"date":133,"type":21},"2027-12-01",{"name":41,"class":42},5,{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":143,"targetDuration":4,"studyType":54,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":43},"100632947","efficacy-heterogeneity-of-lactobacillus-paracasei-lc19-on-type-2-diabetes-100632947","NCT07520305","Efficacy Heterogeneity of Lactobacillus Paracasei LC19 on Type 2 Diabetes","A Study of the Efficacy Heterogeneity of Lactobacillus Paracasei LC19 Intervention in Patients With Newly Diagnosed Type 2 Diabetes","Inclusion Criteria:\n\n* Age 18-65 years, both genders eligible\n* Drug-naive patients with newly diagnosed type 2 diabetes\n* Subjects with screening HbA1c ≥ 7.0% and ≤ 9.0%\n* Subjects understand the nature, significance, potential benefits, inconvenience, and risks and procedure of the study, and voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n* Other types of diabetes except T2D: type 1 diabetes (including adult latent autoimmune diabetes), special type diabetes, or secondary diabetes (such as acromegaly or Cushing\\'s syndrome, etc.)\n* Subjects with acute diabetic complications such as diabetic ketoacidosis or diabetic hyperosmolar coma in the past 6 months\n* Subjects with history of hypoglycemia in the past 6 months\n* Subjects with history of New York Heart Association class (NYHA) grade of heart function ≥ III or serious cardiovascular diseases (myocardial infarction, or with the history of cardiac interventional therapy or stent implantation, valve disease or valve repair, unstable angina, transient ischemic attack or stroke) within 6 months before the screening period\n* Subjects with history of chronic active hepatitis and\u002For severe liver dysfunction, renal dysfunction, and thyroid dysfunction\n* Subjects with a medical history of malignant tumor\n* Subjects with history of gastrointestinal diseases that affect food digestion and absorption (such as severe diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease, active gastrointestinal ulcers, acute cholecystitis, etc.) or with a history of intestinal resection or other gastrointestinal surgery (such as cholecystectomy) within one year before the screening period\n* Subjects with history of surgery, or severe trauma in the past 6 months, or planning to undergo surgery during the study period\n* Subjects suffering from severe infections, severe anemia, or neutropenia\n* Subjects pregnant or in lactation, or those planning to become pregnant or impregnate during or within 3 months after the study period\n* Subjects with history of receiving immunosuppressants, steroids, anti diarrheal drugs, antibiotics, lipid-lowering drugs, or other gastrointestinal motility medications within the past 3 months\n* Subjects using other medications that can affect blood glucose in the past 3 months\n* Subjects with consumption of other probiotic or prebiotic products in the past 3 months before secreening\n* Subjects with lactose intolerance, known or suspected allergy to probiotics used in experiments, history of drug allergies or allergic diseases\n* Subjects with weight fluctuations ≥ 5kg in the past 3 months or planning to take medication to control weight during the study period\n* Subjects with history of mental illness or epilepsy, or taking antidepressant medications\n* Subjects with history of alcohol abuse (for men, alcohol consumption exceeding 40 grams per day and for women, exceeding 20 grams per day)\n* Subjects have participated in any other clinical study in the past 3 months",{"count":144,"type":21},70,[78],"This is a single-arm study to investigate the heterogeneity of glycemic response to Lactobacillus paracasei LC19 in patients with newly diagnosed type 2 diabetes. Participants will receive LC19 for 12 weeks, and changes in glycemic control will be evaluated.",[148],"Type 2 Diabetes","2026-04-03",{"date":151,"type":35},"2026-04-09",{"date":153,"type":21},"2026-04-20",{"date":155,"type":21},"2028-03-31",{"name":41,"class":42},{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":54,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":176,"locationsCount":4},"100630688","transpulmonary-pressure-guided-mechanical-ventilation-strategy-in-right-ventricular-protection-in-patients-with-ards-100630688","NCT07490925","Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With ARDS","Application of Transpulmonary Pressure-guided Mechanical Ventilation Strategy in Right Ventricular Protection in Patients With Acute Respiratory Distress Syndrome Caused by Pneumonia","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. ARDS caused by pneumonia (New Global Definition of ARDS)\n3. PaO2\u002FFiO2≤200mmHg\n4. Received invasive mechanical ventilation\n5. Sign the informed consent form\n\nExclusion Criteria:\n\n1. Invasive mechanical ventilation duration \\> 48 hours\n2. History of pulmonary hypertension caused by various reasons\n3. Severe arrhythmia\n4. BMI\\>30kg\u002Fm2\n5. Contraindications to inserting an esophageal catheter (including recent esophageal injury or surgery, severe coagulopathy (platelets \\\u003C 5×10⁹\u002FL or INR \\> 4)\n6. Pregnant and lactating women\n7. Lung transplant recipient\n8. High-risk factors for increased intracranial pressure (including intracranial hemorrhage, cerebral contusion, cerebral edema, intracranial space-occupying lesions, etc.)\n9. Active air leakage in the lungs (pneumothorax, mediastinal emphysema, bronchopleural fistula, air leakage from closed thoracic drainage tubes, etc.)\n10. Neuromuscular disease\n11. Already received salvage measures (iNO, ECMO, prone position, high-frequency oscillatory ventilation)\n12. Severe liver failure\n13. Participated in other ARDS-related studies within 30 days",{"count":165,"type":21},180,[78],"To verify whether the transpulmonary pressure-guided mechanical ventilation strategy can reduce right ventricular involvement, especially the incidence of acute cor pulmonale (ACP), in patients with moderate to severe ARDS induced by pneumonia compared with the currently widely used right ventricular protective mechanical ventilation strategy.",[169],"ARDS (Moderate or Severe)","2026-03-22",{"date":172,"type":35},"2026-03-24",{"date":174,"type":21},"2026-04-01",{"date":39,"type":21},{"name":41,"class":42},{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":17,"minAge":185,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},"100622389","impact-copd-cohort-china-100622389","NCT07382986","IMPACT COPD Cohort (China)","Integrative Medicine Program for COPD With Comorbidity Management","IMPACT","Inclusion Criteria:\n\nAge 40-80 years; Diagnosis of chronic obstructive pulmonary disease (COPD) according to the 2025 GOLD criteria.\n\nExclusion Criteria:\n\nAcute exacerbation of COPD within the past 4 weeks; Presence of other pulmonary diseases causing chronic respiratory failure in addition to COPD, such as severe bronchiectasis, pneumoconiosis, post-tuberculosis destroyed lung, chest wall deformity, or neuromuscular disease; Cystic fibrosis or interstitial lung disease; Severe respiratory failure requiring long-term mechanical ventilation via tracheostomy; History of lung or other organ transplantation; Severe pleural disease or chest wall abnormalities that interfere with imaging or pulmonary function assessment; Lung cancer or other malignancy with widespread metastatic disease; Previous or current chemotherapy and\u002For radiotherapy that may affect pulmonary function or structural assessment; Uncontrolled rheumatic\u002Fautoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus); HIV infection; Long-term use of immunosuppressive agents or systemic corticosteroids; Severe organ dysfunction, such as severe cardiac, hepatic, or renal failure, or severe pulmonary arterial hypertension; Hospitalization due to myocardial infarction, heart failure, or other cardiovascular events within the past 3 months; Major surgery involving the chest, abdomen, or eyes within the past 3 months; Presence of intrathoracic metallic foreign bodies or implants that interfere with imaging assessment (e.g., pacemaker, implantable cardioverter-defibrillator, metallic prosthetic valves, other metallic devices, or shrapnel); Allergy to any component of the investigational Chinese herbal compound formula(s); Allergy to any component of ICS+LABA+LAMA therapy or to inhaler propellants\u002Fexcipients; Unable to accept and wear wearable devices; Pregnant or breastfeeding women; Long-term bedridden status, loss of ability to perform activities of daily living, or life expectancy \\\u003C1 year; Dementia or other cognitive impairment preventing informed consent and follow-up; Living far from the study center, or planned relocation within the next 3 years, making follow-up infeasible; Current participation in another interventional clinical trial involving the respiratory system; Refusal to provide written informed consent.","40 Years","80 Years",{"count":188,"type":21},10000,"Chronic obstructive pulmonary disease (COPD) is a major chronic respiratory condition with high prevalence of multimorbidity. COPD and comorbidities interact dynamically, contributing to symptom fluctuation, acute exacerbations, hospitalization, and long-term disease progression.\n\nThe IMPACT COPD Cohort (China) is a multicenter prospective observational cohort designed to establish a real-world evidence base for integrative Chinese-Western medicine management of COPD with comorbidities. The cohort integrates conventional clinical assessments (symptoms, questionnaires, spirometry, imaging, and biomarkers) with continuous multisensor digital monitoring (e.g., heart rate, blood pressure, activity, sleep patterns, and other physiological and behavioral measures) and digital Traditional Chinese Medicine (TCM) phenotyping (e.g., tongue, pulse, and facial diagnostics).\n\nThe study aims to characterize risk profiles of high-risk populations and patients with confirmed comorbidities, develop and validate prediction models for comorbidity risk and acute exacerbation events, and support evidence generation for long-term management strategies with early screening and risk warning capabilities across hospital, community, and home settings.",[191,192],"Chronic Obstructive Pulmonary Disease (COPD)","Multimorbidities","2026-03-17",{"date":195,"type":35},"2026-03-19",{"date":197,"type":35},"2026-02-26",{"date":199,"type":21},"2030-02-25",{"name":41,"class":42},4,{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":43},"100265737","a-clinical-cohort-study-of-pneumonia-in-respiratory-intensive-care-unit-100265737","NCT02738645","A Clinical Cohort Study of Pneumonia in Respiratory Intensive Care Unit","Inclusion Criteria:\n\n* admit in RICU because of pneumonia of any causes\n* anticipated length of hospital stay more than 72h\n\nExclusion Criteria:\n\n* admit in RICU because of other causes except pneumonia\n* do not agree to join this study\n* admit in RICU for the second time\n* anticipated length of hospital stay less than 72h",{"count":209,"type":21},800,"From 2003 when Severe Acute Respiratory Syndromes (SARS) appeared，many new types of respiratory viruses emerge in endlessly. Therefore, the epidemiology and the clinical character has changed quietly, especially severe pneumonia. This cohort study aim to obtain the contents of severe pneumonia patients in Respiratory Intensive Care Unit (RICU). Through the clinical data analysis, the investigators could get the information of the pneumonia caused by different reasons, such as morbidity and mortality, risk factors, clinical symptoms and radiographic changes, the respiratory support parameter and so on. The investigators hope the result could guide them do the clinical work of severe pneumonia better in the future.",[212],"Pneumonia","2026-03-16",{"date":215,"type":35},"2026-03-18",{"date":217,"type":35},"2016-06",{"date":219,"type":21},"2026-12-31",{"name":41,"class":42},{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":228,"sex":17,"minAge":229,"maxAge":230,"enrollmentInfo":231,"targetDuration":233,"studyType":22,"phases":4,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":43},"100629289","investigation-and-classification-of-treatable-traits-in-patients-with-chronic-airway-diseases-100629289","NCT07472738","Investigation and Classification of Treatable Traits in Patients With Chronic Airway Diseases","An Observational Study for the Investigation and Classification of Treatable Traits in Patients With Chronic Airway Diseases","Inclusion Criteria:\n\n* Inclusion Criteria for Chronic Airway Disease Patients:\n\n  1. Age 20-75 years.\n  2. Meets the diagnostic criteria for COPD according to the 2022 GOLD guidelines OR meets the diagnostic criteria for asthma according to the 2022 GINA guidelines.\n  3. Willing and able to provide informed consent.\n* Inclusion Criteria for Healthy Controls:\n\n  1. Age ≥20 years.\n  2. No history of asthma symptoms or diagnosis of chronic respiratory diseases such as asthma or COPD.\n  3. Willing and able to provide informed consent and comply with the study protocol.\n\nExclusion Criteria:\n\n* (applies to all participants):\n\n  1. Respiratory tract infection, COPD acute exacerbation, or asthma acute exacerbation within the past 3 months.\n  2. Presence of other diseases causing significant lung tissue destruction, such as severe bronchiectasis or tuberculosis.\n  3. History of thoracic or abdominal surgery within the past 3 months.\n  4. Heart rate \\>120 beats per minute.\n  5. Ongoing anti-tuberculosis treatment.\n  6. Presence of other severe, uncontrolled systemic diseases.\n  7. Pregnant or lactating women.",true,"20 Years","75 Years",{"count":232,"type":21},950,"1 Year","This research study focuses on chronic airway diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. These conditions make it difficult for patients to breathe, but breathing difficulty (dyspnea) is often perceived very differently. Some patients may feel severe distress with mild breathing problems, while others might not notice significant breathing issues even when lung function is poor. This difference in perception is termed \"dyspnea perception.\"\n\nThe main goal of this study is to understand how dyspnea perception varies among patients with chronic airway diseases. The investigators aim to determine if patients can be grouped into different subtypes based on the perception of breathing difficulties. The study will also investigate how these subtypes relate to other treatable characteristics, such as blood cell counts, allergy test results, and findings from lung function tests and brain scans.\n\nApproximately 800 patients with COPD or asthma and 150 healthy volunteers will participate. Participants will answer questionnaires, undergo lung function tests, provide blood samples, and a subset will undergo a special brain scan (functional MRI). No new treatments will be assigned; instead, these characteristics will be observed and measured over time.\n\nIt is hoped that this study will help doctors better understand chronic airway diseases and lead to more personalized management strategies for patients in the future.",[236,191,237],"Asthma (Diagnosis)","Chronic Airway Diseases",[239,240,241,242,243],"Treatable Traits","Dyspnea Perception","Clinical Phenotyping","Observational Study","Functional Magnetic Resonance Imaging (fMRI)","2026-03-12",{"date":213,"type":35},{"date":247,"type":35},"2025-05-07",{"date":249,"type":21},"2027-12",{"name":41,"class":42},{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":259,"maxAge":230,"enrollmentInfo":260,"targetDuration":4,"studyType":54,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":43},"100596762","hyperbaric-oxygen-after-stroke-thrombectomy-a-multicenter-randomized-trial-on-safety-and-efficacy-100596762","NCT07049692","Hyperbaric Oxygen After Stroke Thrombectomy: A Multicenter Randomized Trial on Safety and Efficacy","Evaluation of the Efficacy and Safety of Hyperbaric Oxygen in Patients After Endovascular Treatment for Acute Ischemic Stroke: A Multicenter, Open-label, Randomized Controlled Clinical Trial","NOTICE-1","Inclusion Criteria:\n\n* 35-75 years\n* The symptoms and signs are consistent with acute anterior circulation ischemic stroke. The immediate postoperative angiographic recanalization grade was ≥ 2b.\n* Neurological deficit score at the time of enrollment: 5 ≤ NIHSS ≤ 15 points\n* Consciousness status (NIHSS 1a-1b items): 0-1 point\n* Pre-stroke functional status (mRS score): 0-1\n* Time from surgery to randomization grouping: ≤ 72 hours\n* Patient or legal representative who signed the informed consent form\n* Preoperative CT angiography or magnetic resonance angiography confirmed large vessel occlusion (internal carotid artery or middle cerebral artery M1 segment) that was consistent with the symptoms and signs; And the area supplied by the middle cerebral artery in the brain is less than 1\u002F3.\n* A lberta S troke P rogram E arly C T S core ≥ 6\n\nExclusion Criteria:\n\n* Subjects with HBO contraindications or intolerance\n* Postprocedural imaging identified either procedure-related subarachnoid hemorrhage or hemorrhagic transformation\n* Based on the medical history, it is suspected that the cerebral embolism is caused by sepsis or infective endocarditis\n* Expected lifespan \\\u003C 90 days\n* Severe heart, liver and kidneys failure\n* Pregnancy\n* Hereditary or acquired bleeding tendency, deficiency of coagulation factors, recent use of oral anticoagulants with an international normalized ratio (INR) \\> 3 or activated partial thromboplastin time (APTT) exceeding the normal value by more than 3 times\n* Baseline platelet count \\\u003C 50×10 9\u002FL\n* Baseline blood glucose is less than 2.78 mmol\u002FL or greater than 22.2 mmol\u002FL.\n* Unstable vital signs (heart rate ≤ 50 beats\u002Fmin or ≥ 120 beats\u002Fmin, oxygen saturation ≤ 90%, respiration ≥ 30 breaths\u002Fmin or ≤ 10 breaths\u002Fmin);\n* Hypertension that cannot be controlled by medication: Systolic blood pressure ≥ 160 mmHg, or diastolic blood pressure ≥ 100 mmHg;\n* Suspected of having acute myocardial infarction;\n* Currently involving in the research of other projects related to drugs or medical devices.\n* CT or MRI scans revealed intracranial tumors (except for cerebellar meningiomas) and intracranial arteriovenous malformations.\n* Based on the medical history and CT or MRI findings, a diagnosis of internal carotid artery dissection or aortic dissection is suspected;\n* Based on the medical history and CT or MRI findings, cerebral vasculitis is suspected.\n* Based on the clinical evidence of multiple vascular regions being occluded (either in the bilateral anterior circulation or anterior\u002Fposterior circulation) or bilateral infarction or multi-region infarction as detected by CT angiography or magnetic resonance angiography;\n* CT or magnetic resonance imaging shows a significant midline shift effect (\\> 0.5 cm);\n* CT angiography or magnetic resonance angiography confirmed the presence of cerebral vasculitis or cerebral vasculitis syndrome;","35 Years",{"count":261,"type":21},424,[78],"1. The goal of this clinical trial is to evaluate the efficacy and safety of hyperbaric oxygen (HBO)in stroke patients after endovascular treatment\n2. The main questions it aims to answer is:\n\n   Whether HBO can improve the prognosis of ischemic stroke patients after endovascular treatment?\n3. Participants will:\n\nreceive HBO (1.6 Atmosphere Absolute，1.6ATA)，Once a day, for 1 hour each time, for 5 days a week (it can be non-consecutive days), the total course of treatment is 10 times.\n\nundergo three scheduled face to face or telephone follow-up assessments during the 12-month period following HBO.",[265],"Acute Ischemic Stroke",[267,268,269],"HBO","acute ischemic stroke","endovascular treatment","2025-12-25",{"date":272,"type":35},"2025-12-31",{"date":274,"type":21},"2026-02-01",{"date":276,"type":21},"2028-03-30",{"name":41,"class":42},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":284,"enrollmentInfo":285,"targetDuration":287,"studyType":22,"phases":4,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":295,"leadSponsor":297,"locationsCount":4},"100617785","the-effect-of-semaglutide-on-the-intestinal-flora-in-obesity-100617785","NCT07323134","The Effect of Semaglutide on the Intestinal Flora in Obesity","Inclusion Criteria:\n\n* 18 to 60 years old;\n* BMI ≥ 30kg\u002Fm²;\n* At least one self-reported history of unsuccessful lifestyle weight loss;\n* Subjects who agree to participate in the project and sign the informed consent form.\n\nExclusion Criteria:\n\n* Weight changes within 3 months prior to screening (self-reported) \\>5%;\n* Having received any drug treatment for obesity within the three months prior to screening;\n* The application of hypoglycemic drugs within 3 months before screening, or HbA1c≥ 6.5%, or a history of type 1 or type 2 diabetes;\n* Participants who have received treatment with immunosuppressants, steroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering drugs and\u002For other gastrointestinal motility drugs within 3 months prior to screening;\n* Previously diagnosed overweight or obesity due to endocrine causes, such as Cushing's syndrome, etc;\n* Triglycerides ≥500mg\u002FdL (5.65mmol\u002FL) during screening;\n* It is known that there are clinically significant gastric emptying abnormalities (e.g., severe diabetic gastroparesis or gastric outlet obstruction), a history of gastrointestinal diseases and surgical history;\n* Abnormal thyroid function;\n* History of mental illness;\n* History of multiple endocrine tumors or medullary thyroid cancer, family history, or calcitonin ≥6pg\u002FmL;\n* Abnormal liver function during screening, that is, alanine aminotransferase and\u002For aspartate aminotransferase \\> 3\\*ULN;\n* Abnormal renal function during screening, that is, the estimated glomerular filtration rate is less than 60mL\u002Fmin\u002F1.75m2;\n* History of cardiovascular diseases;\n* History of malignant tumors;\n* Pregnancy or lactation;\n* As determined by the researcher, there are other physical, psychological or other conditions that make one unsuitable to participate in the trial.","60 Years",{"count":286,"type":21},40,"3 Months","For obese individuals, semaglutide treatment was adopted. By using multi-omics techniques such as fecal metagenomic sequencing and based on in vitro strain screening platforms, the effects and specific mechanisms of semaglutide on the intestinal flora of obese patients were clarified.",[290],"Obesity","2025-12-23",{"date":293,"type":35},"2026-01-07",{"date":274,"type":21},{"date":296,"type":21},"2026-08-01",{"name":41,"class":42},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":304,"targetDuration":4,"studyType":54,"phases":306,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":324},"100603400","the-study-about-the-identification-of-treatable-traits-of-severe-asthma-and-the-construction-of-personalized-treatment-system-100603400","NCT07136025","The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System","Inclusion Criteria:\n\n* Age ≥18 years, and \\\u003C80 years with a definite diagnosis of asthma for at least 6 months\n* Patients met the 2024 GINA criteria for severe asthma, which was defined as \"uncontrolled\" asthma (frequent asthma symptoms, or frequent acute exacerbations) despite high-dose inhaled corticosteroids (ICS) plus long-acting β2-receptor antagonists (LABAs), or worsening of symptoms after slight tapering of high-dose therapy.\n* They were willing to accept multi-disciplinary and multi-dimensional evaluation and signed informed consent\n* Informed consent was obtained and patients were able to participate in the study and 6-month follow-up according to the protocol\n\nExclusion Criteria:\n\n* The presence of numerous other lung tissue destructive diseases, such as severe bronchiectasis or pulmonary tuberculosis.\n* Chest surgery or abdominal surgery in the past 3 months\n* Eye surgery had been performed within the past 3 months\n* Myocardial infarction within the previous 3 months\n* Anti-tuberculosis treatment is ongoing\n* Women who are pregnant and lactating\n* Macrolide use within 4 weeks before the screening period\n* Treatment with anti-ige, anti-IL-5, or anti-IL-5R within 4 weeks before the screening period\n* Inhaled ICS+LABA+ long-acting anticholinergic agent (LAMA) for 4 weeks prior to the screening period 4. Allergy to macrolides\n* QTc interval prolongation \\>480ms\n* Taking medications that interact with azithromycin, causing QTc prolongation or existing ECG abnormalities, may lead to arrhythmia",{"count":305,"type":21},200,[78],"Severe asthma is a complex and heterogeneous disease. Patients with severe asthma can present with different types of airway inflammation, and are often accompanied by a variety of comorbidities and risk factors. Identification of potentially modifiable factors affecting prognosis, that is, \"treatable characteristics\", and individualized bundle management based on these characteristics may help to improve the quality of life of patients with asthma and improve the level of asthma control. Through joint research, this project aims to evaluate the treatable characteristics of asthma in patients with severe asthma in tertiary hospitals across the country, including lung function, fractional exhaled nitric oxide, blood routine, allergen IgE, chest CT, and a detailed questionnaire. The distribution of treatable characteristics of patients with severe asthma and its impact on the quality of life or asthma control level of patients were investigated. For patients with severe asthma, multidisciplinary consultation and shared decision-making were used to establish an individualized bundle management model based on the treatable characteristics of severe asthma. A 6-month randomized parallel controlled clinical trial was conducted to determine whether this model was superior to conventional management in improving the quality of life or asthma control in patients with severe asthma. The implementation of this project will build a new model of individualized management of severe asthma based on treatable characteristics and improve the management level of severe asthma",[309],"Asthma",[311,312,313,314,315],"treatable traits","asthma","sever","AQLQ","ACQ","2025-08-18",{"date":318,"type":35},"2025-08-22",{"date":320,"type":35},"2025-02-01",{"date":322,"type":21},"2029-01-31",{"name":41,"class":42},10,{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":230,"enrollmentInfo":332,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":334,"conditions":335,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":346,"locationsCount":43},"100520872","effect-of-transpulmonary-mp-on-prognosis-of-patients-with-severe-ards-treated-with-vv-ecmo-100520872","NCT06062212","Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO","Effect of Transpulmonary Mechanical Power on the Prognosis of Patients With Severe Acute Respiratory Distress Syndrome Treated With Venovenous Extracorporeal Membrane Oxygenation","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of Berlin's definition for ARDS;\n2. Receiving VV-ECMO support.\n\nExclusion Criteria:\n\n1. Patients had been on high pressure (Ppeak \\>35 cm H2O) and a high fraction of inspired oxygen (FiO2\\>0.8) ventilation for \\>7 days;\n2. Patients had a contraindication to heparinization;\n3. Patients had an irreversible neurological injury;\n4. Patients had severe chronic lung disease with life expectancy \\\u003C6 months.",{"count":333,"type":21},100,"Venovenous extracorporeal membrane oxygenation (VV-ECMO) is a salvage treatment for severe acute respiratory distress syndrome (ARDS). With the large-scale implementation of VV-ECMO in critical care medicine departments in China, significant progress has been made in treating severe ARDS. However, the patient mortality rate remains high. The pathophysiological essence of ARDS is an imbalance between the body's oxygen supply and demand, causing tissue and cell hypoxia, organ dysfunction, and even death. The VV-ECMO treatment process still requires mechanical ventilation assistance. However, inappropriate mechanical ventilation settings can lead to ventilator-related lung injury (VILI). In recent years, mechanical power has gradually attracted everyone's attention and is considered the cause of VILI. The transpulmonary mechanical power is more accurate to the energy directly performed to the lung tissue. Transpulmonary mechanical energy has a specific value in judging the prognosis of mechanically ventilated patients, but its clinical significance in treating patients with VV-ECMO is unclear. This study aimed to explore the value of transpulmonary mechanical power in predicting the prognosis of patients with severe ARDS patients treated with VV-ECMO.",[336,337,338,339],"Acute Respiratory Distress Syndrome","Extracorporeal Membrane Oxygenation","Mechanical Power","Transpulmonary Mechanical Power","2025-07-02",{"date":342,"type":35},"2025-07-03",{"date":344,"type":35},"2023-10-01",{"date":272,"type":21},{"name":41,"class":42},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":366,"locationsCount":43},"100527821","evaluation-of-membrane-lung-function-in-high-altitude-regions-100527821","NCT06152744","Evaluation of Membrane Lung Function in High-altitude Regions","Evaluation of Membrane Lung Function for Patients Receiving Venovenous Extracorporeal Membrane Oxygenation in High-altitude Regions","Inclusion Criteria:\n\n* Receiving ECMO support\n\nExclusion Criteria:\n\n* Unable to obtain post-membrane blood gas\n* Pregnancy\n* Patients cannot receive anticoagulation\n* Refusal to participate in the trial","70 Years",{"count":286,"type":21},"Over the last 20 years, extracorporeal membrane oxygenation (ECMO) has been used to support adult patients with respiratory or cardiac failure who are unlikely to survive conventional treatment methods. ECMO circuit, pump, and oxygenator technology improvements permit safer perfusion for extended periods. The prolonged use of an ECMO circuit increases the risk of membrane lung (ML) dysfunction. The ML is responsible for taking in oxygen and removing carbon dioxide. The non-biologic surface of the ML triggers inflammatory and coagulation pathways, resulting in the formation of blood clots, breakdown of fibrin, and activation of white blood cells, which ultimately leads to ML dysfunction. Coagulation and fibrinolysis activation can cause systemic coagulopathy or hemolysis, and the deposition of blood clots can block blood flow. Moreover, the accumulation of moisture in the gas phase and the buildup of protein and cellular debris in the blood phase may contribute to shunt and dead-space physiology, respectively, impairing the exchange of gases. These three categories-hematologic abnormalities, mechanical obstruction, and inadequate gas exchange-account for most ML exchanges. Worsening oxygenation during ECMO should prompt quantification of oxygen transfer. ML exchange is indicated when the ML can no longer meet the patient's oxygen demand. The partial pressure of Post-ML arterial oxygen less than 200 mmHg is the most important consideration in this decision. In some high-altitude regions of China, ECMO treatment is also routinely conducted. The experiences above are derived from low-altitude areas, and whether they apply in high-altitude regions is still being determined. This study aimed to explore the significantly lower membrane lung oxygen uptake in high-altitude regions compared to low-altitude areas.",[337,358,359],"Membrane Lung Function","High Altitude","2025-06-13",{"date":362,"type":35},"2025-06-17",{"date":364,"type":35},"2023-12-05",{"date":272,"type":21},{"name":41,"class":42},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":54,"phases":376,"briefSummary":377,"conditions":378,"keywords":379,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":385,"locationsCount":43},"100502485","early-pp-monitored-by-eit-in-patients-with-ards-100502485","NCT05822869","Early PP Monitored by EIT in Patients With ARDS","Early Prone Positioning Monitored by Electrical Impedance Tomography in Patients With Acute Respiratory Distress Syndrome","Inclusion Criteria:\n\n1. Age ≥ 18 years old；\n2. Meets the diagnostic criteria for ARDS according to the 2012 Berlin definition；\n3. Intubation with invasive mechanical ventilation time \\\u003C 36 hours；\n4. PaO2\u002FFiO2 \\\u003C 150mmHg.\n\nExclusion Criteria:\n\n1. Contraindication to the prone position;\n2. Contraindication to the EIT;\n3. Patients have received extracorporeal membrane oxygenation treatment.",{"count":375,"type":21},60,[78],"Acute Respiratory Distress Syndrome (ARDS) is a syndrome characterized by respiratory distress and refractory hypoxemia caused by pulmonary and extra-pulmonary factors. Despite improvements in diagnosis and treatment in recent years, the mortality rate of severe ARDS is still around 40%. The distribution of lung lesions in ARDS patients is significantly gravity-dependent. Even with lung-protective ventilation strategies, tidal volume is concentrated in the ventral lung region, leading to ventilator-associated lung injury. Prone position ventilation can increase ventilation to the dorsal lung tissue and improve the ventilation-perfusion ratio, thus improving oxygenation. During prone position ventilation in ARDS patients, lung-protective ventilation strategies should be maintained, but with different respiratory mechanics from the supine position, requiring adjustment of ventilator parameters. Electrical Impedance Tomography (EIT) technology can be used for bedside monitoring of mechanically ventilated patients, providing real-time feedback on the patient's ventilation status and having great potential for clinical applications. Investigators believes that EIT monitoring during prone position ventilation in ARDS patients can individualize lung-protective ventilation strategies, minimize alveolar overdistension and collapse, improve the weaning success rate of invasive ventilation, and ultimately improve patient prognosis.",[336],[380],"acute respiratory distress syndrome, prone position, electrical impedance tomography, mechanical ventilation",{"date":362,"type":35},{"date":383,"type":35},"2023-05-01",{"date":272,"type":21},{"name":41,"class":42},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":228,"sex":17,"minAge":284,"maxAge":4,"enrollmentInfo":393,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":394,"conditions":395,"keywords":398,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":43},"100569289","exploring-the-predictive-value-of-electroencephalography-features-in-perioperative-neurocognitive-disorders-following-cardiovascular-surgery-100569289","NCT06692309","Exploring the Predictive Value of Electroencephalography Features in Perioperative Neurocognitive Disorders Following Cardiovascular Surgery","To Explore the Predictive Value of Electroencephalography Features in Perioperative Neurocognitive Disorders in Patients Undergoing Cardiovascular Surgery Under General Anaesthesia: a Single-centre Prospective Observational Study","Inclusion Criteria:\n\n1. Written informed consent\n2. undergoing coronary artery bypass surgery or valve replacement surgery under general anaesthesia\n3. ASA grade: II-IV\n4. older than 60 years\n5. Able to complete cognitive function tests\n\nExclusion criteria:\n\n1. history of severe neurological diseases and psychiatric diseases\n2. history of drug abuse\n3. severe hearing or vision impairment\n4. preoperative delirium\n5. serious adverse reactions such as cardiac arrest and cardiopulmonary resuscitation during surgery\n6. patients undergoing secondary surgery in a short period\n7. participation in concurrent clinical trials",{"count":333,"type":21},"To explore the predictive value of Electroencephalography features in Perioperative Neurocognitive Disorders in patients undergoing cardiovascular surgery under general anesthesia",[396,397],"Cardiovascular Surgery","Perioperative Neurocognitive Disorders",[399],"Perioperative Neurocognitive Disorders;Electroencephalography","2025-05-25",{"date":402,"type":35},"2025-05-30",{"date":404,"type":35},"2023-03-01",{"date":406,"type":21},"2026-02-28",{"name":41,"class":42},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":51,"enrollmentInfo":416,"targetDuration":4,"studyType":54,"phases":418,"briefSummary":419,"conditions":420,"keywords":423,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":43},"100591450","study-on-the-treatment-of-nonthrombotic-obstructive-pulmonary-hypertension-100591450","NCT06980584","Study on the Treatment of Nonthrombotic Obstructive Pulmonary Hypertension","Analysis of Clinical Characteristics and Follow-Up Study on Treatment of Nonthrombotic Obstructive Pulmonary Hypertension: Interventional Study","ACCT-NOPH","Inclusion Criteria:\n\n1. Diagnosed with fibrosing mediastinitis between November 2024 and November 2026, aged between 18 and 85 years.\n2. The patient presented with symptoms of chest tightness, shortness of breath, and reduced exercise tolerance.\n3. Chest CT revealed mediastinal lymph node compression of the pulmonary artery, with evidence of pulmonary hypertension consistent with the patient's symptoms.\n4. The subject signed the informed consent form prior to participation and is able to comply with the study protocol and one-year follow-up.\n\nExclusion Criteria:\n\n1. Currently in the active phase of infection, including but not limited to tuberculosis, Histoplasma capsulatum, and Aspergillus infections;\n2. The underlying primary disease, such as sarcoidosis, Behcet's disease, or uncontrolled IgG4-related disease, is currently not well controlled.\n3. Before treatment, a large amount of pleural effusion was still present.\n4. Pulmonary function tests (PFT) showed FEV1 \\\u003C30% of the predicted value, FEV1\u002FFVC \\\u003C30%, and DLCO \\\u003C30%.\n5. There are contraindications to bronchoscopy or endovascular intervention.\n6. Complicated by other end-stage organ dysfunction, such as Child-Pugh class C liver function or stage IV chronic renal failure.\n7. Complicated by severe immunosuppression.",{"count":417,"type":21},48,[78],"Through a randomized controlled trial (RCT) design, this study aiming to evaluated the efficacy and safety of rituximab lymph node injection combined with pulmonary vascular interventional therapy in treating fibrosing mediastinal pulmonary hypertension (FM-PH).Eligible participants were randomly assigned to either the combined treatment group, receiving both pulmonary vascular intervention and rituximab lymph node injection, or the interventional-only group, which received pulmonary vascular intervention alone. At 3, 6, and 12 months post-treatment, the efficacy was assessed based on symptom improvement, hemodynamic changes, lesion volume reduction, etc. Safety was mainly evaluated by comparing adverse event incidence between the two groups.",[421,422],"Fibrosing Mediastinitis","Pulmonary Hypertension",[424,425,426],"Rituximab","Endobronchial Ultrasound","Pulmonary Vascular Intervention","2025-05-20",{"date":429,"type":35},"2025-05-23",{"date":431,"type":35},"2025-02-10",{"date":433,"type":21},"2027-10-31",{"name":41,"class":42},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":441,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":54,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":454,"leadSponsor":455,"locationsCount":4},"100590896","effects-of-pulmonary-rehabilitation-on-quality-of-life-and-health-in-pulmonary-arterial-hypertension-patients-100590896","NCT06973382","Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients","Intervention Study of a Comprehensive Pulmonary Rehabilitation Program on Quality of Life and Prognosis in Patients With Pulmonary Arterial Hypertension","EPRQoL-PAH","Inclusion Criteria:Confirmed PH Diagnosis:\n\nRight heart catheterization-confirmed pulmonary hypertension\n\nMeets 2022 ESC\u002FERS Guidelines diagnostic criteria for:\n\n* Group 1 (PAH) or\n* Group 4 (CTEPH\u002Fother pulmonary artery obstructions)\n\nStabilized Treatment Status:\n\nGroup 1 (PAH): Received ≥3 months of targeted drug therapy\n\nGroup 4 (CTEPH): Completed ≥6 sessions of BPA\\* or reached therapeutic endpoint\n\nFunctional Capacity:\n\nWHO Functional Class I-III\n\nAge: ≥18 years\n\nConsent: Willing to provide written informed consent -\n\nExclusion Criteria:Physical Limitations:\n\nUnable to perform pulmonary rehabilitation exercises due to disability or congenital malformations\n\nCardiopulmonary Testing Contraindications:\n\nMedically unfit to complete CPET (cardiopulmonary exercise testing) after evaluation\n\nPoor Compliance:\n\nHistory of non-adherence making protocol completion unlikely\n\nLife Expectancy:\n\nPrognosis ≤1 year\n\n\\-",{"count":444,"type":21},84,[78],"Pulmonary hypertension (PH) is a major global health concern, affecting approximately 1% of the world's population. With global aging and increased life expectancy, its incidence continues to rise. PH is a progressive and disabling disease, with studies showing its progression correlates with worsening symptoms and increased mortality. Even with targeted medications, the prognosis remains poor across PH subtypes, with PAH patients showing only a 49% 7-year survival rate. The 2022 ESC\u002FERS guidelines emphasize that PH management requires a comprehensive, multidisciplinary approach. Beyond pharmacological and surgical treatments, rehabilitation has demonstrated benefits in improving exercise capacity, quality of life, functional class, and peak oxygen consumption. However, research on specific and effective comprehensive pulmonary rehabilitation programs remains lacking.",[448,449],"PAH","CTEPH","2025-05-14",{"date":452,"type":35},"2025-05-15",{"date":427,"type":21},{"date":433,"type":21},{"name":41,"class":42},{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":284,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":54,"phases":464,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":4},"100586761","a-individualized-physical-function-improvement-program-for-frailty-elderly-using-goal-attainment-scaling-gas-as-evaluation-method-protocol-for-a-randomized-controlled-trial-100586761","NCT06919575","A Individualized Physical Function Improvement Program for Frailty Elderly Using Goal Attainment Scaling (GAS) as Evaluation Method: Protocol for a Randomized Controlled Trial","The inclusion criteria were the following: (1)≥60-years old; (2) recognized as frailty by Fried scale.\n\nThe exclusion criteria were the following: (1) considered with life expectancy \\\u003C 1 year such as advanced cancer patients; (2) difficult to communicate with such as patients with severe cognitive impairment (Mini Mental State Examination score ≤ 17); (3) severe hearing disord.",{"count":463,"type":21},160,[78],"Frailty refers to the age-related decline in physiological functions，that is associated with adverse outcomes. Frailty is a dynamic reversible state, that requires a comprehensive individualized management. Goal Attainment Scaling (GAS) is a structured, individualized method for setting and evaluating progress toward personalized goals.\n\nWe conducted a randomized clinical trial of an individualized intervention program using GAS as evaluation method designed to improve physical functional in frailty elderly. A total of 160 individuals aged ≥60 years, who fulfill the Fried scale of frailty will be recruited from Beijing Chaoyang Hospital, Capital Medical University. All participants set personalized goals through GAS. Patients in the intervention group receive individualized interventions, implement tailored measures based on personalized goals to reverse the frailty state.The participants will be followed-up for 3 months and 24 months.\n\nThis protocol would be established to examine the efficiency of targeted individualized intervention for frailty based on the GAS. If a positive consequence could be obtained, the results of this study will provide critical data for management of frailty in the elderly, that can be carried out in routine clinical practice.",[467],"Elderly","2025-04-02",{"date":470,"type":35},"2025-04-09",{"date":472,"type":21},"2025-05-01",{"date":474,"type":21},"2027-08-01",{"name":41,"class":42},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":284,"enrollmentInfo":483,"targetDuration":4,"studyType":54,"phases":485,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":494,"locationsCount":4},"100579553","semaglutides-weight-loss-effects-in-obesity-100579553","NCT06825793","Semaglutide's Weight Loss Effects in Obesity","Clinical Assessment of Semaglutide-Induced Weight Reduction in Obese Populations","Inclusion Criteria:\n\n* Age 18-60 years\n* BMI ≥ 30 kg\u002Fm²\n* At least one self-reported unsuccessful attempt at lifestyle weight loss\n\nExclusion Criteria:\n\n* Weight change (self-reported) \\> 5% in the past 3 months prior to screening\n* Use of any medication for obesity indication in the past 3 months prior to screening.\n* Use of antidiabetic medications in the past 3 months, or HbA1c ≥ 6.5%, or a history of Type 1 or Type 2 diabetes.\n* Use of immunosuppressants, corticosteroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering medications, and\u002For other gastrointestinal motility drugs in the past 3 months prior to screening.\n* A history of endocrine-related overweight or obesity diagnoses, such as Cushing's syndrome.\n* Triglycerides ≥ 500 mg\u002FdL (5.65 mmol\u002FL) at screening.\n* Known clinically significant gastric emptying abnormalities (e.g., severe diabetic gastroparesis or gastric outlet obstruction), gastrointestinal diseases, or surgical history.\n* Thyroid dysfunction.\n* History of mental illness.\n* History or family history of multiple endocrine neoplasia or medullary thyroid cancer, or calcitonin ≥ 6 pg\u002FmL.\n* Abnormal liver function at screening, defined as alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 3\\*ULN.\n* Abnormal kidney function at screening, defined as estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.75m².\n* History of cardiovascular disease.\n* History of malignancy.\n* Pregnancy or breastfeeding.\n* Any other physiological, psychological, or other conditions deemed by the investigator as unsuitable for participation in the trial.",{"count":484,"type":21},56,[78],"This is a non-randomized, concurrent, parallel-controlled clinical trial. The objective of this trial is to determine the relationship between weight loss responsiveness to semaglutide in obese patients and their gut microbiota.",[290],"2025-02-08",{"date":490,"type":35},"2025-02-13",{"date":492,"type":21},"2025-02-20",{"date":86,"type":21},{"name":41,"class":42},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":228,"sex":17,"minAge":259,"maxAge":96,"enrollmentInfo":502,"targetDuration":4,"studyType":54,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":515,"locationsCount":43},"100560258","eryag-laser-and-air-polishing-application-in-periodontal-treatment-100560258","NCT06574802","Er:YAG Laser and Air Polishing Application in Periodontal Treatment","Combined Application of Er:YAG Laser and Sub-gingival Air Polishing Powder in Treatment of Periodontitis: A Split-mouth, Randomized Controlled Trial","Inclusion Criteria:\n\n* 1\\) aged 35-65 years old, in good systemic healthy;\n* 2\\) clinically diagnosed with generalized stage Ⅱ or stage Ⅲ periodontitis;\n* 3\\) a minimum of 20 teeth\n\nExclusion Criteria:\n\n* 1\\) pregnancy or recent pregnancy plans;\n* 2\\) had received periodontal treatment within the previous 6 months;\n* 3\\) taken antibiotics within the previous 3 months;\n* 4\\) had diabetes;\n* 5\\) obvious malocclusion, history of orthodontic treatment, or a habit of mouth breathing.",{"count":375,"type":21},[78],"Periodontitis (gum disease) is an infection of the gums that can lead to tooth loss. In recent years, many types of dental lasers or other devices have been used for the non-surgical treatment of periodontal diseases. However, it remains unclear whether the combined application of laser and air polishing is effective as an adjuvant treatment for periodontitis. The purpose of this study is to compare the use of combined application of Er:YAG laser and sub-gingival air polishing powder, with the treatment of Er:YAG laser only, in periodontal diseases treatment in a Chinese population.",[506],"Periodontitis",[508],"generalized, stage Ⅱ or stage Ⅲ","2025-02-05",{"date":511,"type":35},"2025-02-07",{"date":513,"type":35},"2024-09-04",{"date":249,"type":21},{"name":41,"class":42},{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":96,"enrollmentInfo":523,"targetDuration":4,"studyType":54,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":531,"locationsCount":43},"100565226","efficacy-of-lactobacillus-paracasei-lc19-on-type-2-diabetes-100565226","NCT06639425","Efficacy of Lactobacillus Paracasei LC19 on Type 2 Diabetes","Efficacy of Lactobacillus Paracasei LC19 on Newly Diagnosed Type 2 Diabetes","Inclusion Criteria:\n\n* Age 18-65 years, both genders eligible\n* Drug-naive patients with newly diagnosed type 2 diabetes\n* Subjects with screening HbA1c ≥ 7.0% and ≤ 9.0%\n* Subjects understand the nature, significance, potential benefits, inconvenience, and risks and procedure of the study, and voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n* Other types of diabetes except T2D: type 1 diabetes (including adult latent autoimmune diabetes), special type diabetes, or secondary diabetes (such as acromegaly or Cushing\\'s syndrome, etc.)\n* Subjects with acute diabetic complications such as diabetic ketoacidosis or diabetic hyperosmolar coma in the past 6 months\n* Subjects with history of hypoglycemia in the past 6 months\n* Subjects with history of New York Heart Association class (NYHA) grade of heart function ≥ III or serious cardiovascular diseases (myocardial infarction, or with the history of cardiac interventional therapy or stent implantation, valve disease or valve repair, unstable angina, transient ischemic attack or stroke) within 6 months before the screening period\n* Subjects with history of chronic active hepatitis and\u002For severe liver dysfunction, renal dysfunction, and thyroid dysfunction\n* Subjects with a medical history of malignant tumor\n* Subjects with history of gastrointestinal diseases that affect food digestion and absorption (such as severe diarrhea, constipation, irritable bowel syndrome, inflammatory bowel disease, active gastrointestinal ulcers, acute cholecystitis, etc.) or with a history of intestinal resection or other gastrointestinal surgery (such as cholecystectomy) within one year before the screening period\n* Subjects with history of surgery, or severe trauma in the past 6 months, or planning to undergo surgery during the study period\n* Subjects suffering from severe infections, severe anemia, or neutropenia\n* Subjects pregnant or in lactation, or those planning to become pregnant or impregnate during or within 3 months after the study period\n* Subjects with history of receiving immunosuppressants, steroids, anti diarrheal drugs, antibiotics, lipid-lowering drugs, or other gastrointestinal motility medications within the past 3 months;\n* Subjects using other medications that can affect blood glucose in the past 3 months\n* Subjects with consumption of other probiotic or prebiotic products in the past 3 months before secreening\n* Subjects with lactose intolerance, known or suspected allergy to probiotics used in experiments, history of drug allergies or allergic diseases\n* Subjects with weight fluctuations ≥ 5kg in the past 3 months or planning to take medication to control weight during the study period\n* Subjects with history of mental illness or epilepsy, or taking antidepressant medications\n* Subjects with history of alcohol abuse (for men, alcohol consumption exceeding 40 grams per day and for women, exceeding 20 grams per day)\n* Subjects have participated in any other clinical study in the past 3 months",{"count":375,"type":21},[78],"This is a randomized, double-blind, placebo-controlled clinical trial. The objective of this trial is to determine whether Lactobacillus paracasei LC19 supplementation has a positive effect on glucose lowering in patients with type 2 diabetes (T2D).",[148],{"date":511,"type":35},{"date":529,"type":35},"2024-10-12",{"date":219,"type":21},{"name":41,"class":42},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":54,"phases":541,"briefSummary":542,"conditions":543,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":43},"100569267","impact-of-hi-nppv-vs-li-nppv-on-tolerance-among-aecopd-patients-100569267","NCT06692023","Impact of HI-NPPV Vs LI-NPPV on Tolerance Among AECOPD Patients","Impact of High-Intensity-NIV Vs Low-intensity-NIV on Subjective Tolerance Amomg Patients with AECOPD : a Randomised Cross-over Pilot Study","Inclusion Criteria:\n\n* AECOPD confirmed by the 2019 criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD);\n* Arterial pH \\\u003C7.35 and PaCO2 \\>45 mmHg at screening entry;\n* PaCO2 \\>45 mmHg after a 6-hour trial of low-intensity NPPV.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Excessive respiratory secretions with weak cough\n* Upper airway obstruction\n* Recent oral, facial, or cranial trauma or surgery\n* Recent gastric or esophageal surgery\n* Presence of restrictive ventilatory dysfunction (eg, consolidation or removal of at least one pulmonary lobe, massive pleural effusion, chest wall deformity, continuous strapping with thoracic or abdominal bandage, or severe abdominal distension)\n* Active upper gastrointestinal bleeding\n* Cardiac or respiratory arrest\n* Arterial oxygen tension\u002Ffraction of inspired oxygen (PaO2\u002FFiO2) \\\u003C100 mmHg\n* Pneumothorax\n* Obvious emphysematous bullae confirmed by chest CT scan\n* Ventricular arrhythmia or myocardial ischemia\n* Severe hemodynamic instability (mean arterial pressure \\\u003C65 mmHg)\n* Severe metabolic acidosis (pH \\\u003C7.20 and bicarbonate \\\u003C22 mmol\u002FL)\n* Refusal to receive NPPV or give informed consent\n* Prior endotracheal intubation or tracheostomy during the current hospitalization\n* A do-not-intubate order",{"count":540,"type":21},20,[78],"To determine whether high-intensity NPPV, compared with low-intensity NPPV, could have an effect on the subjective tolerance in patients with an AECOPD and hypercapnia.",[544],"Acute Exacerbation of Chronic Obstructive Pulmonary Disease","2024-11-14",{"date":547,"type":35},"2024-11-18",{"date":549,"type":21},"2024-12",{"date":551,"type":21},"2025-10",{"name":41,"class":42},{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":186,"enrollmentInfo":560,"targetDuration":4,"studyType":54,"phases":562,"briefSummary":563,"conditions":564,"keywords":565,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":43},"100432829","phase-4-effect-of-postoperative-prolonged-sedation-with-dexmedetomidine-after-successful-reperfusion-with-evt-on-long-term-prognosis-in-patients-with-ais-ppdet-100432829","NCT04916197","Effect of Postoperative Prolonged Sedation With Dexmedetomidine After Successful Reperfusion With EVT on Long-term Prognosis in Patients With AIS (PPDET)","Effect of Postoperative Prolonged Sedation With Dexmedetomidine After Successful Reperfusion With Endovascular Thrombectomy on Long-term Prognosis in Patients With Acute Ischemic Stroke (PPDET)","Inclusion Criteria:\n\n* 2≤NIHSS≤25\n* mRS score before stroke was less than 3\n* Acute ischemic stroke (including anterior circulation)\n* mTICI rate 2b or 3\n* According to the 2018 AHA\u002FASA guidelines for the management of acute ischemic stroke, patients who plan to receive mechanical thrombectomy under local anesthesia and sedation\n* Informed consent was signed by patient or legal representative\n\nExclusion Criteria:\n\n* Intracerebral hemorrhage occurred in the responsible vessel area in the past 6 weeks\n* Patients who had received stent treatment at the responsible vessel in the past\n* Neurological function was restored at or before angiography\n* Patients who are allergic to heparin, aspirin, clopidogrel, rapamycin, lactic acid polymer, poly (n-butyl methacrylate), stainless steel, anesthetics and contrast agents or have contraindications\n* Hemoglobin was less than 70g\u002FL, platelet count was less than 50×109\u002FL, international normalized ratio (INR) greater than 1.5 (irreversible), there are uncorrectable bleeding factors\n* Blood glucose \\\u003C 2.7 mmol\u002FL or \\> 22.2 mmol\u002FL\n* Severe liver or kidney disfunction, ALT\\>3 times the upper limit of normal value or AST\\>3 times the upper limit of normal value, creatinine\\>1.5 times the upper limit of normal value\n* Pregnant or lactating women\n* Previous history of mental illness\n* Stroke with other acute diseases or postoperative stroke of other operation\n* Heart rate less than 50bpm, second or third degree of atrioventricular block (except for pacemaker implantation), systolic blood pressure less than 90mmHg (two vasoactive drugs were already infused continuously )",{"count":561,"type":21},368,[56],"Dexmedetomidine can attenuate the activity of the sympathetic nervous system under stress response and improve ischemia-reperfusion injury. The investigators hypothesized that the prolonged sedation of dexmedetomidine after successful reperfusion of endovascular thrombectomy may improve the clinical outcome of acute ischemic stroke patients.",[265],[566,567,568],"Endovascular thrombectomy","Dexmedetomidine","Modified Rankin Scale","2023-12-19",{"date":571,"type":35},"2023-12-20",{"date":573,"type":21},"2024-03-01",{"date":575,"type":21},"2026-12",{"name":41,"class":42},""]